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Abstract
Background: Chemotherapy is an important component in the treatment paradigm for breast cancers. However, the
resistance of cancer cells to chemotherapeutic agents frequently results in the subsequent recurrence and metastasis.
Identification of molecular markers to predict treatment outcome is therefore warranted. The aim of the present study was
to evaluate whether expression of circulating microRNAs (miRNAs) can predict clinical outcome in breast cancer patients
treated with adjuvant chemotherapy.
Methodology/Principal Findings: Circulating miRNAs in blood serum prior to treatment were determined by quantitative
Real-Time PCR in 56 breast cancer patients with invasive ductal carcinoma and pre-operative neoadjuvant chemotherapy.
Proliferating cell nuclear antigen (PCNA) immunostaining and TUNEL were performed in surgical samples to determine the
effects of chemotherapy on cancer cell proliferation and apoptosis, respectively. Among the miRNAs tested, only miR-125b
was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients (n=26,
46%; p=0.008). In addition, breast cancers with high miR-125b expression had higher percentage of proliferating cells and
lower percentage of apoptotic cells in the corresponding surgical specimens obtained after neoadjuvant chemotherapy.
Increased resistance to anticancer drug was observed in vitro in breast cancer cells with ectopic miR-125b expression;
conversely, reducing miR-125b level sensitized breast cancer cells to chemotherapy. Moreover, we demonstrated that the
E2F3 was a direct target of miR-125b in breast cancer cells.
Conclusions/Significance: These data suggest that circulating miR-125b expression is associated with chemotherapeutic
resistance of breast cancer. This finding has important implications in the development of targeted therapeutics for
overcoming chemotherapeutic resistance in novel anti-cancer strategies.
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Introduction
Breast cancer is the leading cause of cancer and the second
leading cause of cancer death in American women [1], and its
incidence is increasing in many countries including China [2].
Chemotherapy is an important component in the treatment
paradigm for breast cancers. However, despite a rapid shrinkage
in tumor mass following chemotherapeutic cycles, the resistance of
cancer cells to chemotherapeutic agents frequently results in the
subsequent recurrence and metastasis of cancer [3]. To data, there
is no validated sensitivity and/or resistance predictive factor
available in clinical settings and the mechanisms involved in
cancer cell chemoresistance are still largely unknown. Therefore, it
is in urgent need to search for circulating markers and identify
signaling pathways in breast cancer patients resistant to chemo-
therapy.
The molecular mechanisms that may contribute to chemother-
apeutic resistance in breast cancers include overexpression of
ATP-binding cassette transporters, anti-apoptotic factors and cell
cycle deregulation [4–6]. However, targeting any single molecule
is not sufficient to reverse chemotherapeutic resistance [7],
suggesting that multiple molecular pathways may contribute to
the sensitivity of breast cancer cells to chemotherapy.
MicroRNAs (miRNAs) are a group of non-coding, single-
stranded RNAs of ,22 nucleotides, which regulate gene
expression by binding to the 39-untranslated region (UTR) of
target mRNAs, repressing mRNA translation or cleaving target
mRNA [8]. As master regulators of gene expression, miRNAs are
involved in modulating multiple cellular pathways, including cell
proliferation, differentiation, and apoptosis, and thus may function
as oncogenes or tumor suppressing genes [9,10]. Importantly,
circulating miRNAs have been detected as potential blood-based
biomarkers for cancer detection [11–14]. Among them, oncogenic
miRNAs, including miR-10b [15], miR-34a [16], miR-125b [17],
miR-155 [18] etc, have been reported to be related to breast
cancer. In recent years, some miRNAs have been reported to be
involved in drug-resistance. Inhibition of miR-221 or miR-222
expression has been shown to sensitize MDA-MB-468 cells to
tamoxifen-induced cell growth arrest and apoptosis [19]. Ectopic
miR-34a expression resulted in cell cycle arrest and growth
inhibition and attenuated chemoresistance to the anticancer drug,
camptothecin, by inducing apoptosis [20]. To date, however, there
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chemotherapeutic resistance of breast cancers.
The aim of the present study was to evaluate potential biological
markers to predict outcome from adjuvant chemotherapy.
Therefore, we have performed an integrative analysis of the
expression of miR-10b, miR-34a, miR-125b and miR-155 in the
serum of advanced breast cancer patients, with known patholog-
ical and treatment characteristics. We identified an association of
circulating miR-125b level with chemotherapeutic response. In
addition, the effects of overexpression and knockdown of miR-
125b on chemotherapeutic resistance was investigated by in vitro
assays.
Results
Circulating miRNA expression profiles and correlation
with clinical outcome
Expression of 4 miRNAs, miR-10b, -34a, -125b and -155, was
profiled in the serum because of their established relevance to
breast cancer [15–18]. Consistent with previous reports, the levels
of miR-10b and miR-155 were significantly higher in the early
stage (Stage II, n=35) and late stage (Stage III, n=21) breast
cancer patients than in healthy controls (n=10) (Fig. 1). In
addition, the late stage breast cancer patients had significantly
higher level of miR-155 than early stage patients (Fig. 1 and
Table 1). Although early stage breast cancer patients had similar
miR-125b level to healthy controls, late stage patients had on
average 3.5-fold higher mean values of miR-125b than early stage
patients and healthy controls (p,0.01, Fig. 1 and Table 1).
Circulating miR-34 did not differ significantly in each comparison.
Table 1 depicted the correlation of the circulating miRNA levels
in 56 patients, who had advanced ductal breast cancer and
received pre-operative neoadjuvant chemotherapy, with clinical
and histopathological factors. To determine the differences in the
relative expression profiles, we performed univariate analyses of
the Mann Whitney-U test. Expression levels of miR-125b and
miR-155 were related to disease stage with higher miRNA levels in
higher stage disease (p#0.02), but lack of significant association
with estrogen receptor (ER), progesterone receptor (PR) and
epidermal growth factor receptor 2 (HER2) status. Furthermore,
blood levels of miR-125b were significantly associated with tumor
grade and lymph node metastasis of the patients (p#0.04). In
contrast, expression of preoperative circulating miR-10b and miR-
34a did not differ significantly in each comparison.
Circulating miR-125b expression correlated with
chemotherapeutic resistance of breast cancer patients
To determine whether the circulating miRNA expression levels
were associated with chemotherapeutic efficacy, therapeutic
response was evaluated by radiologic Response Evaluation
Criteria in Solid Tumors (RECIST) as well as PCNA immuno-
staining for cell proliferation and TUNEL assay for apoptotic
index in surgical specimens after chemotherapy. According to
RECIST, 30 patients (54%) responded to chemotherapy with PR
or CR; 26 patients (46%) were not responsive with SD or PD.
Among the circulating miRNAs, only miR-125b was significantly
associated with therapeutic response, exhibiting higher expression
level in non-responsive patients (p=0.008, Table 2). In addition,
breast cancers with high miR-125b expression prior to chemo-
therapy had higher percentage of proliferating cells and lower
percentage of apoptotic cells in the corresponding surgical
specimens obtained after neoadjuvant chemotherapy (Fig. 2A
and B), suggesting that miR-125b expression in breast cancers was
reversely correlated with apoptosis and proliferation inhibition
induced by chemotherapy. Responders and non-responders for
chemotherapy exhibited similar expression levels of miR-10b, 34a
and 155 (Table 2).
MiR-125b expression correlated with chemotherapeutic
resistance in primary breast cancer cells
To further determine whether expression of miR-125b might be
correlated with chemotherapeutic response, we isolated primary
cancer cells from the biopsies of 11 breast cancer patients obtained
prior to chemotherapy and correlated miR-125b expression levels
with the efficacy of chemotherapy. Among all the 11 patients who
received neoadjuvant chemotherapy, 6 patients had PR or CR,
while the other 5 patients had PD or SD. The miR-125b
expression levels were significantly higher in breast cancers with
PD/SD than those with PR/CR (8.162.3 fold, p,0.001, Fig. 3A).
Similarly, the IC50 of 5-FU for breast cancer cells with PD/SD
was significant higher than those with PR/CR based on the dose–
response curves (4.862.7 vs. 20.468.6, p=0.002, Fig. 3B).
Furthermore, knockdown of miR-125b using an antisense
sequence significantly decreased IC50 of 5-FU for breast cancers
with PD/SD to the similar levels as those with PR/CR (Fig. 3B).
These findings demonstrate that a higher expression level of miR-
125b is associated with poor clinical response of primary breast
cancers to chemotherapy.
Involvement of miR-125b in chemotherapeutic resistance
in breast cancer cells
In order to directly evaluate the contribution of miR-125b to
chemotherapeutic response, we investigated the role of miR-125b
in chemotherapy resistance in breast cancer cell lines, MCF-7,
T47D, BT20 and MDA-MB-231. Among these cells, MCF-7
exhibited the lowest endogenous miR-125b (Fig. 4A), whereas
MDA-MB-231 cells have 3.161.2 (mean6SD) fold higher miR-
125b expression than MCF-7 (p=0.03). Based on the dose–
response curves, the IC50 of 5-FU was calculated as 8 mM for
MCF-7, 12 mM for T47D, 10 mM for BT20 and 20 mM for MDA-
MB-231, respectively. These concentrations were used in the
following experiments. MiR-125b overexpression was induced
using miRNA mimics. Compared to negative control, overexpres-
sion of miR-125b markedly inhibited 5-FU-induced cytotoxicity in
all of the cell lines tested (Fig. 4B). Moreover, overexpression of
Figure 1. Levels of circulating miRNAs in breast cancer patients
and healthy controls. Relative levels of circulating miR-10b, miR-34a,
miR-125b and miR-155 were measured in healthy individuals (n=10)
and clinical stage II patients (n=35) and stage III patients (n=21) by
quantitative RT-PCR. Data represented mean 6 SD. *p,0.05, **p,0.01
compared to healthy controls; #p,0.05 compared to clinical stage II
patients.
doi:10.1371/journal.pone.0034210.g001
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increased 5-FU resistance in a miR-125b dose-dependent manner
in MCF-7 cells (Fig. 4C). Furthermore, the expression of miR-
125b decreased 5-FU-induced cytotoxicity and increased 5-FU
resistance under various concentration of 5-FU treatment in
MCF-7 cells (Fig. 4D).
Based on the above observation, we further investigated
whether reduced miR-125b may sensitize breast cancer cells to
chemotherapy. MiR-125b antisense were transfected into MDA-
MB-231 (a breast cancer cell line with high endogenous miR-
125b), MCF-7 and FuR/MCF-7 (a MCF-7 breast cancer cell line
induced to be resistant to 5-FU). Knockdown of miR-125b
increased 5-FU induced cytotoxicity in these cells (Fig. 5A and 5B).
More importantly, miR-125b antisense decreased IC50 of FuR/
MCF-7 to the similar level of wild type MCF-7 (Fig. 5B). These
results indicated that miR-125b played an important role in
chemotherapeutic resistance in breast cancer cells.
E2F3 Is a Direct Target of miR-125b in Breast Cancer Cells
To gain further insight into the function of miR-125b in
chemotherapeutic resistance in breast cancer, we used the
prediction programs TargetScan Human 5.1 [21], PicTar [22]
and DIANA microT v3.0 [23] to identify potential miR-125b
target genes. There are 87 predicted targets by all the three
prediction algorithms (Table S1). Functional annotation of the 87
highly conserved target genes by DAVID (http://david.abcc.
ncifcrf.gov/) revealed enrichment of genes involved with tran-
scription regulation, protein transport, chromatin modification,
cell cycle and apoptosis. The three public miRNA databases all
predicted that E2F3 might be a target for miR-125b. We were
particularly interested in E2F3 because of its essential roles in cell
proliferation and apoptosis. Overexpression of miR-125b in MCF-
7 cells significantly down-regulated E2F3 protein level (Fig. 6A). In
contrast, knockdown of miR-125b up-regulated the expression of
E2F3 in MDA-MB-231 cells, which have high expression of
endogenous miR-125b (Fig. 6B). These results indicated that E2F3
expression was regulated by miR-125b in breast cancer cells.
To determine if E2F3 is a direct target of miR-125b, a luciferase
reporter with E2F 39 UTR was constructed and co-transfected
with miRNA mimics into MCF-7 cells (Fig. 6C). Compared to
scramble control, overexpression of miR-125b decreased the
luciferase activity of the reporter with E2F3 39UTR by about 60%
(p=0.002, Fig. 6C). Mutations in the seed sequence of miR-125b
target site restored the repressed luciferase activity (Fig. 6C),
indicating that E2F3 was a direct target of miR-125b.
Discussion
The expanding knowledge of the molecular pathogenesis of
cancer is providing new targets for disease characterization, which
might also be used as new markers to select patients for better
clinical management. In particular, there are a growing number of
studies on miRNAs, which are classified as oncogenes or tumor-
suppressor genes and have a pivotal role in progression and
prognosis of different tumors [9]. In the present study, we
demonstrate that higher circulating miR-125b level is correlated to
Table 1. Patients’ characteristics at the time of primary diagnosis of breast cancer and correlation with serum miRNA levels.
Characteristics Subgroups n Mean (Standard Deviation)
(total 56) miR-10b miR-34a miR-125b miR-155
Clinical stage II 35 (63%) 1.5 (0.7) 3.5 (1.6)
**2.2 (0.4) *0.9 (0.2)
III 21 (38%) 2.2 (1.1) 5.1 (2.6)
**6.8 (2.1) *3.1 (0.6)
Grade II 32 (57%) 1.7 (0.6) 3.8 (1.9)
*2.6 (0.7) 1.5 (0.4)
III 24 (43%) 2.1 (1.0) 4.9 (1.2)
*6.1 (1.9) 2.3 (1.0)
Distant metastasis M0 20 (36%) 1.9 (0.9) 3.9 (1.3) 3.6 (1.1) 1.7 (0.5)
M1-2 36 (64%) 2.1 (0.9) 4.5 (2.1) 5.9 (1.8) 2.1 (1.2)
Node metastasis N1-3 40 (71%) 1.5 (0.7) 3.2 (1.1) *3.1 (0.5) 1.9 (1.0)
N$4 16 (29%) 2.3 (1.2) 5.2 (2.6) *6.3 (1.1) 2.1 (0.9)
ER Negative 13 (23%) 2.1 (1.1) 4.1 (1.9) 4.6 (1.3) 2.2 (1.1)
Positive 43 (77%) 1.9 (0.8) 4.7 (1.9) 4.1 (1.1) 1.9 (0.6)
PR Negative 19 (34%) 1.9 (0.5) 3.9 (1.5) 3.9 (0.9) 1.6 (0.5)
Positive 37 (66%) 2.2 (1.3) 4.6 (2.1) 4.8 (1.5) 2.3 (1.2)
HER2 Negative 46 (82%) 1.7 (0.8) 3.8 (0.9) 3.8 (1.4) 2.1 (0.9)
Positive 10 (18%) 2.0 (1.2) 4.5 (1.3) 4.2 (1.8) 1.7 (1.1)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2 * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034210.t001
Table 2 Correlation of serum miRNA levels and response to
chemotherapy.
n Mean (Stand Deviation)
(total 56)
miR-
10b miR-34a miR-125b
miR-
155
Treatment
response
CR+PR 30 (54%) 1.9 (0.8) 4.1 (1.3)
**1.8 (0.3) 1.9 (0.5)
SD+PD 26 (46%) 2.0 (0.9) 4.3 (1.6)
**7.4 (1.9) 2.1 (0.9)
PCNA Low 35 (63%) 1.5 (0.5) 3.5 (1.2)
**1.9 (0.6) 1.8 (0.6)
High 21 (38%) 2.5 (1.4) 4.7 (1.9)
**6.9 (2.1) 2.2 (0.9)
Apoptotic
index
Low 22 (39%) 1.9 (0.7) 3.9 (1.5) *6.3 (1.3) 2.2 (0.9)
High 34 (61%) 2.1 (1.1) 4.5 (2.2) *2.9 (0.9) 1.6 (1.0)
CR, complete response; PR, partial response; SD, stable disease; PD, disease
progression * p,0.05, ** p,0.01
doi:10.1371/journal.pone.0034210.t002
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adjuvant chemotherapy. In addition, miR-125b expression was
reversely correlated with apoptosis and proliferation inhibition
induced by chemotherapy. Furthermore, breast cancer cells
expressing a higher level of miR-125b were more resistant;
conversely, reducing miR-125b level sensitized breast cancer cells
to chemotherapy. E2F3, as a direct target of miR-125b in breast
cancer cells, may be involved in miR-125b-mediated chemother-
apeutic response. These data suggest that circulating miR-125b
contributes to chemotherapeutic resistance of breast cancer and
serves as a potential marker predicting chemotherapeutic response
and a target for overcoming chemotherapeutic resistance.
The miRNAs currently analyzed were selected from the
comparison of miRNA expression patterns in normal and tumoral
breast tissues, as well as from the results of several preclinical
studies, suggesting their role in tumor progression and sensitivity
[15–18,24,25]. MiR-125b was reported to have complicated
functions as either oncogene-like or tumor suppressor-like in
different cancer types or cell lines. Up-regulation of miR-125b is
not only observed in pancreatic cancer [26], prostate cancer [27],
and acute myeloid leukemia [28], but also promotes cancer cell
proliferation and suppresses p53-dependent apoptosis in human
neuroblastoma cells [29]. However, miR-125b has been reported
to be down-regulated in ovarian carcinoma [30], thyroid
carcinoma [31], and oral squamous cell carcinoma [32] and has
been shown to inhibit cell proliferation and cell cycle progression
in these cancers. Recently, miR-125b was reported to exhibit
under-expressed in breast cancer tissues [33,34]. However, a
precise study using microdissection demonstrated that miR-125
Figure 2. Circulating miR-125b expression correlated to chemotherapeutic response in breast cancer patients. Surgically removed
tumor samples were obtained after neoadjuvant chemotherapy. (A) Percentage of PCNA positive cells was determined by immunohistochemical
staining. (B) Apoptotic index (AI) was expressed as the percentage of TUNEL-positive tumor cells. Circulating miR-125b levels were determined by
quantitative real-time PCR.
doi:10.1371/journal.pone.0034210.g002
Figure 3. MiR-125b expression correlated with chemothera-
peutic resistance in primary breast cancer cells. (A) MiR-125b
expression was determined by quantitative RT-PCR. (B) Primary breast
cancer cells were treated with 5-FU for 48 h with or without miRNA
antisense transfection (100 nM). IC50 was calculated as concentration of
5-FU to produce 50% cell inhibition (Materials and Methods). Data
represented mean 6 SD of primary breast cancer cell cultures from 5
patients with partial or complete response (PR + CR) and from 4
patients with disease progression or stabilization (PD + SD), *p=0.01,
**p=0.002, ***p,0.001.
doi:10.1371/journal.pone.0034210.g003
Figure 4. Involvement of miR-125b in chemotherapeutic
resistance in breast cancer cells. (A) Relative expression levels of
endogenous miR-125b were measured in breast cancer cell lines by
quantitative RT-PCR. Data represented mean 6 SD. *p,0.05 compared
to MCF-7. (B) Breast cancer cells, MCF-7, T47D, BT20 and MDA-MB-231,
were transfected with 100 nM pre-miR-125b and treated with the
indicated concentrations of 5-FU for 48 h. A scramble pre-miRNA
sequence served as a negative control (Ctrl). MCF-7 cells were
transfected with 0, 25, 50, and 100 nM pre-miR-125b and then
incubated with 8 mM 5-FU (C) or were treated with 0, 4, 8, 16, and
32 mM 5-FU for 48 h after transfection of 100 nM miRNA mimics (D).
Cell variability was determined by trypan blue dye exclusion assays.
Data represented mean 6 SD of triplicate experiments. *p,0.05,
**p,0.01, ***p,0.001 compared to Ctrl.
doi:10.1371/journal.pone.0034210.g004
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cells [35]. The under-expression of miR-125b in breast cancer
tissue may be due to loss of myoepithelial cells in cancer tissue
instead of downregulation of miR-125b in cancer cells. Moreover,
other recent studies reported that miR-125b may act as an
oncogene in human breast cancer cells [36] and was related to
resistance of breast cancer cells to paclitaxel [37]. In our study we
show that miR-125b was associated with advanced breast cancer
and increased chemotherapeutic resistance, acting primarily as an
oncogene. One possible explanation for this controversy is the
known diverse nature of miRNA target genes. The net effect of
changes in the expression of a miRNA appears to be the sum of all
impacts on its targets in a cell type-specific and phenotype-specific
manner [38]. The exact association of miR-125b expression and
breast tumor progression is still unclear. Further investigations
with large patient samples and well designed laboratory studies
should be performed in the future to clarify the role of miR-125b
in human breast cancer development.
To achieve a more effective and individualised chemothera-
peutic treatment of breast cancer patients in the future, it is
essential to increase our knowledge in mechanisms responsible for
drug resistance, and to define reliable indicators for response to
therapy. Commonly accepted prognostic factors are lymph node
status, tumor size, histological grade, and patient age. Predictors
for the effect of endocrine treatment, currently used in clinical
routine, are estrogen and progesterone receptor status, and c-
erbB-2 for the effect of trastuzumab [39]. Useful markers for
resistance and/or sensitivity of chemotherapy (FEC and/or
antracyclin based regimes) have not, so far, been identified. Some
markers have shown promising results in a limited number of
studies, e.g. Ki67 [40], p53 [41], multidrug resistance-associated
protein [42] and circulating tumor cells [43,44]. Recent studies
have revealed that a large number of miRNAs are deregulated in
drug resistant or sensitive cancer cell lines [45]. For example,
Kovalchuk et al. [46] found 137 differentially regulated miRNAs
(63 upregulated and 75 downregulated) when comparing doxor-
ubicine-resistant and -sensitive breast cancer cell lines. Circulating
miRNAs have been identified in the serum/plasma and can be
potentially used as biomarkers for tumor characterization and
cancer prognosis [11,47]. To the best of our knowledge, this is the
first study investigating the association of circulating miRNAs and
chemotherapeutic response. We identified miR-125b as a potential
marker predicting chemotherapeutic resistance in breast cancers.
It is well established that miRNAs function via repression of
target gene translation. To date, several targets of miR-125b have
been identified. One recent study showed that pro-apoptotic Bcl-2
antagonist killer 1 (Bak1) was a direct target of miR-125b, and
suppression of Bak1 gene expression through overexpression of
miR-125b inhibited Taxol-induced apoptosis and led to an
increased resistance to Taxol in breast cancer cells [37]. Tumor
suppressor p53 was directly targeted by miR-125b, and overex-
pression of miR-125b inhibited p53-dependent apoptosis in
human neuroblastoma cells and human lung fibroblast cells
[48]. A report showed that ErbB2/HER2 and ErbB3/HER3 were
both targets of miR-125b in breast cancer SKBr3 cells [49].
However, we could not find a significant association between
circulating miR-125 level and HER2 status in breast cancer
patients. Consistent with our results, miR-125b did not induce
ErbB2/HER2 down-regulation in either prostate cancer cells or
breast cancer cells including SKBr3 cells in other reports [27,37].
Utilizing multiple target prediction tools, we identified 87 potential
targets of miR-125b including BMPR1b, an experimentally
Figure 5. Knockdown of miR-125b sensitized breast cancer cells to chemotherapy. MDA-MB-231 (A), MCF-7 and 5-FU resistant FuR/MCF-7
(B) cells were transfected with 100 nM anti-miR-125b or anti-scramble control (Ctrl). Then the cells were treated with the indicated concentrations of
5-FU for 48 h. Data represented mean 6 SD of triplicate experiments. *p,0.05, **p,0.01, ***p,0.001 compared to Ctrl.
doi:10.1371/journal.pone.0034210.g005
Figure 6. E2F3 was a direct target of miR-125b in breast cancer
cells. (A) MCF-7 cells were transfected with 100 nM pre-miR-125b or
pre-scramble control (Ctrl). (B) MDA-MB-231 cells were transfected with
100 nM anti-miR-125b or anti-scramble control (Ctrl). Twenty-four hours
after transfection, nuclear lysates were prepared for Western blotting
with an antibody against E2F3, and TBP was used as a loading control.
(C) MCF-7 cells were co-transfected with luciferase reporter plasmids
with intact or mutant 39UTR of E2F3, pre-miR-125 or pre-scramble
control (Ctrl). Luciferase activity was measured at 48 h post-transfection
using a dual luciferase reporter assay. The results were expressed as
relative luciferase activity (firefly/renilla luciferase). Data represented
mean 6 SD of triplicate experiments. *p=0.002.
doi:10.1371/journal.pone.0034210.g006
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other recently defined targets (MUC1 [51], HER2 [49], BAK1
[37] and ETS1 [17]) are not among our list, reflecting a challenge
of miRNA target identification [52]. By combining the bioinfor-
matic and experimental approaches, our results indicated that
E2F3 expression was regulated by miR-125b through a target site
in the 39UTR in breast cancer cells. E2F3 family of transcription
factors plays a critical role in regulating cell cycle progression and
proliferation [53,54]. Furthermore, E2F3, and in some settings
E2F1, induce apoptosis through p53-dependent or -independent
pathways [54,55]. E2F3 pathway has been associated with
chemotherapy sensitivity in ER-negative cancers [56]. Thus, it is
not surprising that E2F3 be a critical target that mediated the
chemotherapeutic resistance in miR-125b overexpressing breast
cancer cells.
In conclusion, high miR-125b expression in serum was
associated with chemotherapeutic resistance in advanced ductal
carcinoma of breast, and the overexpression of miR-125b caused a
marked inhibition of anticancer drug activity and increased
resistance in breast cancer cells in vitro. Because only 5-FU was
used in our in vitro studies, further investigation will be needed to
validate the role of miR-125b with other chemotherapeutic
reagents. In addition, we demonstrated that E2F3 was a direct
target of miR-125b in breast cancer cells. These data provided
evidence that miR-125b may allow stratification for adjuvant
therapy, thus offering a potential new biomarker for treatment
selection and personalized therapy.
Materials and Methods
Ethics Statement
The Study obtained the permission of the ethics committee of
Dalian medical university and all patients provided written
informed consent.
Patients
Patients receiving chemotherapy treatment for primary invasive
ductal carcinoma of the breast between 01/2009 and 12/2010 at
the Department of General Surgery were reviewed. A total of 56
patients (median age 55, range 36–78) were included in the study.
All the patients underwent pre-operative neoadjuvant chemother-
apy with an association of 5-Florouracil (5-FU), Epirubucin and
Cyclophosphamide (FEC) for 4–6 cycles. Before starting the
treatment, patients received a baseline blood draw for miRNA
expression profiling. Tumor assessment was performed every
3 months by CT-scan and/or chest X-ray coupled with abdomen
ultrasound depending on those used at baseline. Subsequently, the
patients underwent total mastectomy or breast reservation. The
patients with breast reservation received post-operative radiother-
apy. Treatment response was assessed by the RECIST criteria
[57]. Patients achieving complete (CR) or partial (PR) response
were considered as responder; disease stabilization (SD) or disease
progression (PD) considered as non-responder. According to the
clinical response of neoadjuvant chemotherapy, adjuvant FEC or
Taxotere was selectively administered in the patients with PR/CR
or PD/SD. Endocrine therapy was administered for patients with
positive hormonal receptor. Additionally, 10 age-matched healthy
women with no history of cancer and in good health based on self-
report were recruited as controls.
Extraction of total RNA
The mirVana PARIS kit (Ambion) was used to isolate total RNA
from human blood serum according to manufacturer’s instruc-
tions. Four hundred mL of serum samples were incubated with an
equal volume of Denaturation Solution for 5 minutes on ice. The
RNA extraction was performed by acid-phenol:chloroform, and
the precipitation was carried out by ethanol and a filter cartridge.
The extracted RNA was eluted in 100 mL of preheated Elution
Solution and measured on a NanoDrop ND-1000 Spectropho-
tometer (Thermo Scientific). The RNA samples were immediately
stored at 280uC until use.
Quantitative real-time PCR
For quantitative real-time PCR, the miRNA-specific TaqMan
MicroRNA Assays (Applied Biosystems) for miR16 (reference
miR), miR10b, miR34a, miR125b and miR155 were used as
described by the manufacturer. Briefly, 100 ng of total RNA was
reverse transcribed using primers specific to each miRNA target
followed by real-time PCR on a 7900 HT Fast Real-Time PCR
System using TaqMan miRNA primers and probes (Applied
Biosystems). Triplicate samples, validated endogenous controls
and interassay controls were used throughout. MiRNA expression
levels were calculated by the DCt method: DCt = mean value Ct
(reference miR-16) – mean value Ct (miRNA of interest). The
relative expression of miRNA of interest corresponded to the 2
DCt
value.
Immunohistochemistry and Terminal deoxynucleotidyl
transferase (TdT)–mediated dUTP labeling (TUNEL)
The level of PCNA was detected by immunohistochemistry
staining in paraffin-embedded tissue sections. Mouse monoclonal
anti-PCNA antibody (ab29, Abcam) (1:6000 dilutions) were used
as primary antibody. The mouse IgG was added as the negative
control.
TUNEL assay was done using an In situ Apoptosis Detection
Kit (R&D Systems). Briefly, after digesting with Protease K, TdT
reaction mix was applied to the cells for incubation at 37uC for
60 min, followed by incubation with streptavidin horseradish
peroxidase for 10 min. The final reaction of the product was
visualized by 3, 39-diaminobenzidine. Approximately 1,000 tumor
cells were counted (4006) in each section, and apoptotic index (AI)
was expressed as the percentage of TUNEL-positive tumor cells.
The proportion of positive tumor cells was evaluated by two
pathologists who were blinded to the study endpoints. For the
statistical purpose, we divided cases into two groups: low
expression (PCNA#25% or AI#1%) and high expression
(PCNA.25% or AI.1%) [15].
Cell culture and drug treatment
Human breast cancer cell lines, MCF-7, T47D, BT20 and
MDA-MB-231, were purchased from American Type Culture
Collection (ATCC) and grown according to standard protocols.
The different inhibitory concentrations of 5-FU were determined
by generating dose–response curves after treating the cells with
increasing concentrations of 5-FU and analyzing the cell sensitivity
using trypan blue dye exclusion assays. Briefly, the cell suspension
was appropriately diluted with 0.4% trypan blue dye (Sigma-
Aldrich) and hematocytometer was used to estimate the percent-
age of unstained treated cells compared to the control cells. The
inhibition rate was calculated as follows: Inhibition rate=(1-
unstained treated cells/control cells) 6 100. The IC50 (concen-
tration of 5-FU to produce 50% cell inhibition) was determined
and used for further analysis. All experiments were carried in
triplicate.
5-FU resistant MCF-7 (FuR/MCF-7) cells were selected in
stepwise increasing concentrations beginning at 0.1 mM and
ending at 20 mM of 5-FU (Sigma). Cells did not receive next
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treatment. Despite massive cell deaths among the sensitive MCF-7
cells under treatment, the cultures were maintained by regular
changes of medium intermittently increasing the 5-FU concentra-
tion until the surviving cells recovered a normal growth pattern in
the medium with 1 mM 5-FU, which was included in the culture
medium for MCF-7/5-FU to maintain the drug resistance. The
cells were maintained in 5-FU free medium at least 2 weeks before
each experiment.
Primary breast cancer cells were isolated from biopsy samples
using the Cancer Cell Isolation kit (Panomics) following the
manufacturer’s protocol. Briefly, tumor pieces of ,2 mm size were
seeded into six-well culture plates and cultured in RPMI 1640
supplemented with 20% fetal bovine serum, 1% L-glutamine, 1%
MEM nonessential amino acid, and 1% antibiotic/penicillin-
streptomycin solution. Cells were maintained at 37uCi na
humidified atmosphere containing 5% CO2. Cells were harvested
with 0.1% trypsin/0.05% EDTA when the cultures had reached
,80% confluence. These cells were expanded for three to four
subsequent passages and thereafter used for determining miR-
125b expression level and dose–response curves to 5-FU.
Luciferase reporter assay and transfection
Full length 3’UTR of E2F3 gene was amplified by PCR and
inserted into the firefly luciferase reporter immediately down-
stream from the stop codon. Mutation in miR-125b target site was
introduced by PCR amplification using appropriate oligonucleo-
tides. For luciferase assays, MCF-7 cells were transfected in 6-well
plates, using Lipofectamine LTX, with firefly luciferase reporter
vectors (0.7 mg), together with a Renilla luciferase control vector
(0.07 mg) (Promega). For each well, 25 nM miR-125b mimic or a
scramble control miRNA was co-transfected with the reporter
constructs. Luciferase activity was measured 24 hrs after transfec-
tion using the Dual Luciferase Reporter Assay System (Promega).
Firefly luciferase activity was normalized to Renilla luciferase
activity.
MiR-125b overexpression and inhibition were achieved by
transfection of miRIDIAN miRNA mimic (Thermo Scientific) and
LNA antisense oligonucleotides (Exiqon), respectively. Transfec-
tion was performed using Lipofectamine RNAiMAX reagent
(Invitrogen); reverse transfection procedure was performed
according to the manufacture’s instructions.
Western Blot
Nuclear extracts were made using the NE-PER kit (Pierce).
E2F3 and TATA binding protein (TBP, nuclear protein loading
control) were detected using the anti-E2F3 (N-20, Santa Cruz) and
anti-TBP (1TBP18, Abcam) antibodies. For immunoblotting, cell
lysates (20 mg) were resolved on 15% SDS–polyacrylamide gels
and transferred onto polyvinylidene difluoride membranes (Hy-
bond-P; Amersham Biosciences). Membranes were blocked with
2% non-fat milk for 1 h and then incubated with the primary
antibody followed by a horseradish peroxidase-conjugated sec-
ondary antibody, and ECL-PLUS Detection System (Amersham
Biosciences) was used as substrate for chemiluminescent detection.
The band intensity was quantitated using Image J software. Data
were normalized to the intensity of TBP bands.
Statistical analysis
The statistical analyses were performed using the SPSS software
package, version 18.0. The chi square or two-tailed Fischers exact
test was used to identify potential associations of miRNA
concentrations in blood serum with the clinical and histopatho-
logical risk factors of the breast cancer patients. For nonparametric
comparisons, univariate analyses of the Mann Whitney-U test of
two independent variables and bivariate analyses of the Spearman-
Rho test were used. All experiments for cell cultures were
performed at least triplicate and evaluated by Student’s t test.
Data were presented as mean6standard deviation (SD). P,0.05 in
all cases was considered statistically significant.
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